{"id":881451,"date":"2025-09-03T09:35:49","date_gmt":"2025-09-03T13:35:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/"},"modified":"2025-09-03T09:35:49","modified_gmt":"2025-09-03T13:35:49","slug":"astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/","title":{"rendered":"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025<\/b><\/p>\n<p>BOSTON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fastriatx.com%2F&amp;esheet=54317910&amp;newsitemid=20250903703203&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=baaf3298041c045502d5f566485426cc\">Astria Therapeutics, Inc.<\/a> (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology &amp; Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France.<\/p>\n<p>\nStephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, \u201cDemonstration of Early Proof-of-Concept for STAR-0310, a Long-Acting OX40 Receptor Antagonist: Initial Safety, PK, and PD Results from a Phase 1a Trial.\u201d The presentation will take place at 2:15pm CEST on Wednesday, September 17<sup>th<\/sup> in the Paris Nord room.<\/p>\n<p><b>About Astria Therapeutics:<\/b><\/p>\n<p>\nAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.astriatx.com%2F&amp;esheet=54317910&amp;newsitemid=20250903703203&amp;lan=en-US&amp;anchor=www.astriatx.com&amp;index=2&amp;md5=8c3962f90cd5421f6f15488cdef573bf\">www.astriatx.com<\/a>, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250903703203\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250903703203\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations and Media:<br \/>\n<\/b><br \/>Elizabeth Higgins<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@astriatx.com\">investors@astriatx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States North America France Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Other Science Research Pharmaceutical Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250903703203\/en\/2327976\/3\/Astria_Logo_horizontal-fullcolor_TM_1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 BOSTON&#8211;(BUSINESS WIRE)&#8211;Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology &amp; Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France. Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, \u201cDemonstration of Early Proof-of-Concept for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881451","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 BOSTON&#8211;(BUSINESS WIRE)&#8211;Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology &amp; Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France. Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, \u201cDemonstration of Early Proof-of-Concept for &hellip; Continue reading &quot;Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T13:35:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025\",\"datePublished\":\"2025-09-03T13:35:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/\"},\"wordCount\":309,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/\",\"name\":\"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-09-03T13:35:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/","og_locale":"en_US","og_type":"article","og_title":"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 - Market Newsdesk","og_description":"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 BOSTON&#8211;(BUSINESS WIRE)&#8211;Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology &amp; Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France. Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, \u201cDemonstration of Early Proof-of-Concept for &hellip; Continue reading \"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-03T13:35:49+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025","datePublished":"2025-09-03T13:35:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/"},"wordCount":309,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/","name":"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-09-03T13:35:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250903703203r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astria-therapeutics-to-present-initial-data-from-phase-1a-trial-of-star-0310-at-upcoming-european-academy-of-dermatology-venereology-congress-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology &amp; Venereology Congress 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881451"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881451\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}